Atomoxetine Hydrochloride

Attention Deficit Hyperactivity Disorder

Treatment

1 FDA approval

20 Active Studies for Atomoxetine Hydrochloride

What is Atomoxetine Hydrochloride

Atomoxetine

The Generic name of this drug

Treatment Summary

Atomoxetine, also known as Strattera, is a medication used to treat attention deficit hyperactivity disorder (ADHD). It works by increasing the levels of norepinephrine and dopamine in the prefrontal cortex of the brain, which can improve focus and reduce impulsivity and hyperactivity. Atomoxetine is a non-stimulant medication, which makes it a good alternative to stimulant drugs like Ritalin, Adderall, and Concerta. It has fewer side effects than stimulants and has a lower potential for abuse. Atomoxetine is usually prescribed along with other treatments such as psychological therapy,

Strattera

is the brand name

image of different drug pills on a surface

Atomoxetine Hydrochloride Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Strattera

Atomoxetine

2002

183

Approved as Treatment by the FDA

Atomoxetine, commonly known as Strattera, is approved by the FDA for 1 uses like Attention Deficit Hyperactivity Disorder .

Attention Deficit Hyperactivity Disorder

Helps manage Attention Deficit Hyperactivity Disorder (ADHD)

Effectiveness

How Atomoxetine Hydrochloride Affects Patients

Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD). It works by increasing the levels of norepinephrine and dopamine in the brain, which improves ADHD symptoms. However, it can also affect the cardiovascular system, causing an increase in blood pressure and heart rate. Therefore, it should be used cautiously in patients with existing heart or blood vessel issues. In addition, it can cause psychotic or manic symptoms in people without a prior history of such illnesses, so if such symptoms occur the medication should be stopped. Atomoxetine can also increase the risk of suicidal thoughts in children and adolescents with ADHD.

How Atomoxetine Hydrochloride works in the body

Atomoxetine is used to treat ADHD. It works by blocking the reuptake of norepinephrine and serotonin in the brain, which increases their availability and helps reduce symptoms of ADHD. It also affects the glutamatergic system in the brain, which is thought to play a role in ADHD.

When to interrupt dosage

The dosage of Atomoxetine Hydrochloride is contingent upon the diagnosed condition. The quantity of dosage varies, depending on the technique of administration enumerated in the table below.

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

, 10.0 mg, 18.0 mg, 25.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 100.0 mg

Oral, Capsule, Capsule - Oral, , Kit, Kit - Oral

Warnings

Atomoxetine Hydrochloride Contraindications

Condition

Risk Level

Notes

Cardiovascular Diseases

Do Not Combine

advanced arteriosclerosis

Do Not Combine

Hypertensive disease

Do Not Combine

Pulse Frequency

Do Not Combine

Pheochromocytoma

Do Not Combine

Hyperthyroidism

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Atomoxetine may interact with Pulse Frequency

There are 20 known major drug interactions with Atomoxetine Hydrochloride.

Common Atomoxetine Hydrochloride Drug Interactions

Drug Name

Risk Level

Description

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Atomoxetine.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Atomoxetine.

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Atomoxetine.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Atomoxetine.

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Hydroxyzine.

Atomoxetine Hydrochloride Toxicity & Overdose Risk

There have been very few cases of overdose on atomoxetine. In some cases, people have died from mixing atomoxetine with other drugs, but no deaths from overdose of atomoxetine alone have been reported, even when taken in amounts of up to 1400mg. Symptoms of overdose include stomach issues, drowsiness, dizziness, trembling, hyperactivity, agitation, increased heart rate and blood pressure, dry mouth, confusion, and hallucinations. If you suspect an overdose of atomoxetine, contact a poison control center.

image of a doctor in a lab doing drug, clinical research

Atomoxetine Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Atomoxetine Hydrochloride?

At present, 77 active studies are evaluating the potential of Atomoxetine Hydrochloride to treat Attention Deficit Hyperactivity Disorder.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Atomoxetine Hydrochloride Reviews: What are patients saying about Atomoxetine Hydrochloride?

5

Patient Review

9/2/2022

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

From the very first day I took this medication, I noticed a significant difference. My thinking was more clear and focused, anxiety and negative thoughts lessened, and I felt generally more peaceful and content.

5

Patient Review

2/7/2022

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

After years of struggling with anxiety and focus, this medication has completely changed my life for the better. I'm so grateful to have found a doctor that knew this would help me.

4.7

Patient Review

6/13/2014

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

This treatment, in conjunction with Adderall, put me into a manic state. I found that Depakote (750mg) helped me to achieve mental balance. For anxiety, I used Tenex and supplemented it with L-theanine (from green tea). This combination made me more aware and calm, without the drowsy feeling.

4.7

Patient Review

9/19/2017

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

I'm feeling pretty good after taking this drug. I'm more focused and have less energy, but in a calm way. I'm sometimes sleepy, but overall it's a positive experience.

4.3

Patient Review

1/19/2012

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

I was really struggling with my addiction to Vyvanse, so my doctor decided to try Strattera instead. I have to say that it works better for me than any stimulant has in the past. Plus, I don't have to worry about becoming addicted to it.

4

Patient Review

2/26/2021

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

I found this to be much more effective than adderall or ritalin, with none of the jitters, sweating, anxiety, or mood swings. However, I find the effects to be inconsistent. Some days I feel like I haven't taken anything while others I can be a bit of a zombie, but most of the time I feel like a productive normie. Best part is its not a stimulant.

4

Patient Review

8/23/2011

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

3

Patient Review

11/12/2022

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

I experienced no negative side effects, but unfortunately this treatment did not provide any relief for me.

3

Patient Review

10/9/2012

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

It took a little bit of trial and error to get the dosage right, but this medication has been working well for me for several years now.

2.7

Patient Review

10/5/2019

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

This treatment was very painful and resulted in an extremely unpleasant ejaculation.

2.3

Patient Review

3/13/2022

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

As someone with ADHD, this medication just made me feel exhausted and unable to focus on anything. If I took it at night, I would be more hyperactive the next day than if I hadn't taken it at all.

2.3

Patient Review

10/12/2013

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

I'm concerned about the fact that this is a controlled substance.

2.3

Patient Review

10/12/2013

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

I found that this, alongside Adderall, put me in a manic state. I now use depakote 750mg to maintain mental balance, and for anxiety tenex. I also supplement with L-theanine (from green tea), which helps me stay calm and aware.

1.3

Patient Review

11/14/2011

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

On the first day that I took Strattera, I felt like a new person. No anxiety, more organized, and able to focus on one thing at a time. My wife even said that I went from a 1 to an 8. It's amazing how this medication has changed my life and made me feel normal for the first time in 54 years.

1

Patient Review

5/10/2018

Atomoxetine Hydrochloride for Attention Deficit Disorder with Hyperactivity

I had a really negative reaction to this medication. I became nauseous and jittery, and then got a headache that wouldn't go away no matter what painkillers I took. Overall, my health was negatively impacted.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about atomoxetine hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does atomoxetine make you feel?

"Atomoxetine may cause fatigue and drowsiness. It may also make it difficult to fall asleep and stay asleep for some people. Additionally, some people may wake up earlier than usual in the morning and be unable to fall back asleep. If you experience any of these issues, talk to your doctor."

Answered by AI

What are side effects of atomoxetine?

"If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

If you experience any of the following side effects, you should tell your doctor or pharmacist: stomach upset, nausea, vomiting, constipation, tiredness, loss of appetite/weight loss, dry mouth, dizziness, drowsiness, trouble sleeping, or decrease in sexual ability/desire. In addition, women may experience menstrual cramps or missed/irregular periods. If any of these effects persist or worsen, tell your doctor or pharmacist."

Answered by AI

What is atomoxetine Hydrochloride used for?

"Atomoxetine is a medication used to treat ADHD that increases the ability to pay attention and decreases impulsiveness and hyperactivity. Atomoxetine belongs to a class of medications called selective norepinephrine reuptake inhibitors."

Answered by AI

Is atomoxetine the same as Adderall?

"Amphetamines are central nervous system (CNS) stimulants that work by increasing levels of the neurotransmitters dopamine and norepinephrine in the brain. Strattera, on the other hand, is a norepinephrine reuptake inhibitor that also works to increase levels of dopamine and norepinephrine in the brain by preventing them from being taken up by neurons. While Strattera and Adderall are both used to treat ADHD, they are completely different drugs. Adderall is a combination of two drugs in the amphetamine class of medication. Amphetamines are central nervous system (CNS) stimulants that work by increasing levels of the neurotransmitters dopamine and norepinephrine in the brain. Strattera, on the other hand, is a norepinephrine reuptake inhibitor that also works to increase levels of dopamine and norepinephrine in the brain by preventing them from being taken up by neurons."

Answered by AI

Clinical Trials for Atomoxetine Hydrochloride

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Atomoxetine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Atomoxetine Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Atomoxetine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Atomoxetine Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.

Recruiting
Has No Placebo

Montana State University

Have you considered Atomoxetine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Atomoxetine Hydrochloride, we think they might fit your search criteria.
Go to Trials